Moderna shares surged 125% in six months: flu vaccine and new strategy
Moderna (NASDAQ: MRNA) shares closed trading on Friday, June 26, up 12%. Over the past six months, the American biotech giant's stock has surged 125.51% from lows near $46 recorded in early June. This powerful rally is the result of several fundamental factors, which I will break down in detail below.
FDA Vote Eliminates Key Regulatory Risk
The key catalyst was the unanimous decision by the FDA's Vaccines and Related Biological Products Advisory Committee. On June 18, all 9 committee members supported a positive evaluation of the drug mFLUSIVA (mRNA-1010) for people over 50. Such unanimity in the biotech sector is rare and a very strong signal to the market.
This event virtually eliminated regulatory uncertainty ahead of the key decision date of August 5. If the FDA approves mFLUSIVA, it will be the first seasonal flu vaccine based on mRNA technology in the U.S. The market is already pricing in this scenario.
Wall Street Remains Cautious but Raises Forecasts
Analysts at Piper Sandler raised their price target for MRNA to $77, and Jefferies to $53, while maintaining a "hold" rating. However, the median analyst forecast stands at $43.45 — significantly below current trading levels. This suggests Wall Street is not yet ready to fully believe in the stock's long-term potential.
Most experts (16 ratings) recommend holding the asset. Meanwhile, insider transactions are dominated by sales — the last 75 operations were sell-offs. Analysts do not expect significant revenue growth from flu vaccine sales before 2027.
Beyond Vaccines: A New Business Structure
Moderna underwent a reorganization, carving out three divisions: vaccines, oncology, and rare diseases. This news lifted shares by approximately 6.3%. The company also presented an expanded development portfolio at its Science Day event, including programs for in vivo CAR-T and T-cell engagers for oncology and autoimmune diseases.
Plans to invest in manufacturing in Germany, including sites that BioNTech intends to close, led to MRNA shares rising 8–12% over several trading sessions. The market perceived this move as a long-term bet on increasing capacity ahead of new product launches in 2027–2028.
My analysis: Moderna's growth is impressive, but I see signs of overheating. The median analyst forecast of $43.45 versus the current ~$100+ indicates a high risk of a correction. Fundamentally, the company is strong, but investors should exercise caution — the market has already priced in future successes that have yet to be realized.